BACKGROUND: One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacilleCalmette-Guérin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG. METHODS: We report here the first double-blind phase 1 trial of rBCG30 in 35 adults randomized to receive either rBCG30 or parental Tice BCG intradermally. Clinical reactogenicity was assessed, and state-of-the-art immunological assays were used to study Ag85b-specific immune responses induced by both vaccines. RESULTS: Similar clinical reactogenicity occurred with both vaccines. rBCG30 induced significantly increased Ag85b-specific T cell lymphoproliferation, interferon (IFN)-gamma secretion, IFN-gamma enzyme-linked immunospot responses, and direct ex vivo intracellular IFN-gamma responses. Additional flow cytometry studies measuring carboxyfluorescein succinimidyl ester dilution and intracellular cytokine production demonstrated that rBCG30 significantly enhanced the population of Ag85b-specific CD4(+) and CD8(+) T cells capable of concurrent expansion and effector function. More importantly, rBCG30 significantly increased the number of Ag85b-specific T cells capable of inhibiting intracellular mycobacteria. CONCLUSIONS: These results provide proof of principal that rBCG can safely enhance human TB immunity and support further development of rBCG overexpressing Ag85b for TB vaccination.
RCT Entities:
BACKGROUND: One strategy for improving anti-tuberculosis (TB) vaccination involves the use of recombinant bacille Calmette-Guérin (rBCG) overexpressing protective TB antigens. rBCG30, which overexpresses the Mycobacterium tuberculosis secreted antigen Ag85b, was the first rBCG shown to induce significantly greater protection against TB in animals than parental BCG. METHODS: We report here the first double-blind phase 1 trial of rBCG30 in 35 adults randomized to receive either rBCG30 or parental Tice BCG intradermally. Clinical reactogenicity was assessed, and state-of-the-art immunological assays were used to study Ag85b-specific immune responses induced by both vaccines. RESULTS: Similar clinical reactogenicity occurred with both vaccines. rBCG30 induced significantly increased Ag85b-specific T cell lymphoproliferation, interferon (IFN)-gamma secretion, IFN-gamma enzyme-linked immunospot responses, and direct ex vivo intracellular IFN-gamma responses. Additional flow cytometry studies measuring carboxyfluorescein succinimidyl ester dilution and intracellular cytokine production demonstrated that rBCG30 significantly enhanced the population of Ag85b-specific CD4(+) and CD8(+) T cells capable of concurrent expansion and effector function. More importantly, rBCG30 significantly increased the number of Ag85b-specific T cells capable of inhibiting intracellular mycobacteria. CONCLUSIONS: These results provide proof of principal that rBCG can safely enhance human TB immunity and support further development of rBCG overexpressing Ag85b for TB vaccination.
Authors: Daniel F Hoft; Shewangizaw Worku; Beate Kampmann; Christopher C Whalen; Jerrold J Ellner; Christina S Hirsch; Robin B Brown; Rhonda Larkin; Qing Li; Hyun Yun; Richard F Silver Journal: J Infect Dis Date: 2002-10-23 Impact factor: 5.226
Authors: Stephen A Migueles; Alisha C Laborico; W Lesley Shupert; M Shirin Sabbaghian; Ronald Rabin; Claire W Hallahan; Debbie Van Baarle; Stefan Kostense; Frank Miedema; Mary McLaughlin; Linda Ehler; Julia Metcalf; Shuying Liu; Mark Connors Journal: Nat Immunol Date: 2002-10-07 Impact factor: 25.606
Authors: Leander Grode; Peter Seiler; Sven Baumann; Jürgen Hess; Volker Brinkmann; Ali Nasser Eddine; Peggy Mann; Christian Goosmann; Silke Bandermann; Debbie Smith; Gregory J Bancroft; Jean-Marc Reyrat; Dick van Soolingen; Bärbel Raupach; Stefan H E Kaufmann Journal: J Clin Invest Date: 2005-08-18 Impact factor: 14.808
Authors: A Wangoo; T Sparer; I N Brown; V A Snewin; R Janssen; J Thole; H T Cook; R J Shaw; D B Young Journal: J Immunol Date: 2001-03-01 Impact factor: 5.422
Authors: J J Campbell; K E Murphy; E J Kunkel; C E Brightling; D Soler; Z Shen; J Boisvert; H B Greenberg; M A Vierra; S B Goodman; M C Genovese; A J Wardlaw; E C Butcher; L Wu Journal: J Immunol Date: 2001-01-15 Impact factor: 5.422
Authors: S Cho; V Mehra; S Thoma-Uszynski; S Stenger; N Serbina; R J Mazzaccaro; J L Flynn; P F Barnes; S Southwood; E Celis; B R Bloom; R L Modlin; A Sette Journal: Proc Natl Acad Sci U S A Date: 2000-10-24 Impact factor: 11.205
Authors: Steven M Truscott; Getahun Abate; Jeffrey D Price; Claudia Kemper; John P Atkinson; Daniel F Hoft Journal: Infect Immun Date: 2010-10-04 Impact factor: 3.441
Authors: Timothy Lahey; Robert D Arbeit; Muhammad Bakari; C Robert Horsburgh; Mecky Matee; Richard Waddell; Lillian Mtei; Jenni M Vuola; Kisali Pallangyo; C Fordham von Reyn Journal: Vaccine Date: 2010-09-25 Impact factor: 3.641
Authors: Azra Blazevic; Christopher S Eickhoff; Jaime Stanley; Mark R Buller; Jill Schriewer; Eric M Kettelson; Daniel F Hoft Journal: Microbes Infect Date: 2013-10-08 Impact factor: 2.700
Authors: Patricia A Darrah; Diane L Bolton; Andrew A Lackner; Deepak Kaushal; Pyone Pyone Aye; Smriti Mehra; James L Blanchard; Peter J Didier; Chad J Roy; Srinivas S Rao; David A Hokey; Charles A Scanga; Donata R Sizemore; Jerald C Sadoff; Mario Roederer; Robert A Seder Journal: J Immunol Date: 2014-07-14 Impact factor: 5.422
Authors: Myrna C Bonaldo; Mauricio A Martins; Richard Rudersdorf; Philip A Mudd; Jonah B Sacha; Shari M Piaskowski; Patrícia C Costa Neves; Marlon G Veloso de Santana; Lara Vojnov; Saverio Capuano; Eva G Rakasz; Nancy A Wilson; John Fulkerson; Jerald C Sadoff; David I Watkins; Ricardo Galler Journal: J Virol Date: 2010-01-20 Impact factor: 5.103